by David B. Page, Michael Simanonok, Douglas A.
Hanes, Alan Su Digitally automated spatial profiling of immune-tumor cell interactions using multispectral immunofluorescence holds promise as a biomarker to predict outcomes in early-stage breast cancer, but prospective validation and harmonization with existing biomarkers is necessary before clinical adoption. In this Perspective, David Page and colleagues discuss how spatially profiling immune-tumor cell interactions using multispectral immunofluorescence analyses holds promise as a biomarker to predict outcomes in early-stage breast cancer.
PLOS Medicine published a clinical update in Research Highlights on 10 Mar 2026.
The item focuses on Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer.
Review the original article for the full source wording and details.